Current diagnosis and treatment progress of primary myelofibrosis: reports from the 19th European Hematology Association annual congress
10.3760/cma.j.issn.1009-9921.2014.09.006
- VernacularTitle:原发性骨髓纤维化诊疗进展:第19届欧洲血液学会年会报道
- Author:
Danfeng ZHANG
;
Ling PAN
- Publication Type:Journal Article
- Keywords:
Primary myelofibrosis;
Janus kinase 2;
JAK inhibitors;
Therapy;
European Hematology Association annual congress
- From:
Journal of Leukemia & Lymphoma
2014;23(9):525-529
- CountryChina
- Language:Chinese
-
Abstract:
Primary myelofibrosis is a kind of chronic myeloproliferative neoplasms.The discovery of the JAK2V617F mutation as well as other molecular abnormlities underly the pathogenesis of Philadelphia negative myeloproliferative neoplasms (MPN).The initial description of JAK2V617F mutation in 2005,the reporting of calreticulin (CALR) mutations last year and the clinical application of JAK inhibitors,showed the gradually deepening understanding with regard to the pathogenesis and the development of therapeutic strategies for primary myelofibrosis (PMF).This article reviewed the progress in diagnosis,risk stratification of of PMF,the benefits and potential side effect of JAK inhibitors,which reported on the 2014 European Hematology Association annual congress.
